Lupin gets US FDA nod
29 December 2014 | News | By BioSpectrum Bureau
Lupin gets US FDA nod
The company will now market generic version of ViiV Healthcare's Epivir Tablets in the US
Lupin has announced that it has received the US Food and Drug Administration (US FDA) approval to market a generic version of ViiV Healthcare's Epivir Tablets, used in treating HIV infection.
According to the company, it has received final approval for its Lamivudine tablets in strengths of 150 mg and 300 mg.
Epivir tablets had annual US sales of $39.7 million as per IMS MAT September 2014 sales data.
